HealthQuill psoriasis
Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over 50 years, has failed to meet its primary goal of being symptom-free after a year of therapy.
Drugs Health Pharma

Novartis’ drug to treat inflammation of arteries fails in end-stage trials

HQ Team July 3, 2025: Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over.

Read More
Health Medical

Consumption of highly processed food linked to psoriasis flare-up

Bharti Jayshankar December 4, 2024: The link between highly ultra-processed food (UPF) and various health issues such as obesity, diabetes, cardiovascular risks and.

Read More
US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltd’s arm — Dermavant Sciences Ltd., specialising in immuno-dermatology — for $1.2 billion.
Drugs Health Pharma

Organon & Co to buy Riovant’s arm Dermavant Sciences for $1.2 billion

US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltd’s arm — Dermavant Sciences Ltd., specialising in immuno-dermatology — for $1.2 billion.

Read More
Eli Lilly and Company will acquire Dice Therapeutics for $2.4 billion to expand its immunology business, according to an online statement.
Drugs Health Pharma

Eli Lilly to acquire Dice Therapeutics by third quarter for $2.4 billion 

HQ Team June 20, 2023: Eli Lilly and Company will acquire Dice Therapeutics for $2.4 billion to expand its immunology business, according to an.

Read More